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Abstract
Background High budget impact (BI) estimates of new drugs limit access to patients due to concerns regarding affordability 
and displacement effects. The accuracy and methodological quality of BI analyses are often low, potentially mis-informing 
reimbursement decision making. Using hepatitis C as a case study, we aim to quantify the accuracy of the BI predictions 
used in Dutch reimbursement decision-making and to characterize the influence of market-dynamics on actual BI.
Methods We selected hepatitis C direct-acting antivirals (DAAs) that were introduced in the Netherlands between Janu-
ary 2014 and March 2018. Dutch National Health Care Institute (ZIN) BI estimates were derived from the reimbursement 
dossiers. Actual Dutch BI data were provided by FarmInform. BI prediction accuracy was assessed by comparing the ZIN 
BI estimates with the actual BI data.
Results Actual BI, from 1 Jan 2014 to 1 March 2018, was €248 million whilst the BI estimates ranged from €388–€510 
million. The latter figure represents the estimated BI for the reimbursement scenario that was adopted, implying a €275 mil-
lion overestimation. Absent incorporation of timing of regulatory decisions and inadequate correction for the introduction 
of new products were main drivers of BI overestimation, as well as uncertainty regarding the patient population size and the 
impact of the final reimbursement decision.
Discussion BI in reimbursement dossiers largely overestimated actual BI of hepatitis C DAAs. When BI analysis is per-
formed according to existing guidelines, the resulting more accurate BI estimates may lead to better informed reimbursement 
decisions.
Keywords Hepatitis C · Budget impact · Budget impact accuracy · Direct-acting antivirals · Affordability · Pharmaceuticals
JEL Classification I180 · H51
Introduction
The role of budget impact (BI) in healthcare decision-mak-
ing varies across different jurisdictions as recent reviews 
indicate [1–4]. Germany and the USA are examples of juris-
dictions that do not have a formal or informal role for budget 
impact in decision-making. Other countries, for example 
The Netherlands, France and Australia, do have guidance or 
even legislation on BI, but the actual role of BI or the impact 
on decision-making remains rather informal and, moreover, 
politically driven [1–4]. On the other end of the spectrum, 
England has one of the best defined systems with a clear 
role for BI in healthcare decision making [2, 3]. In general, 
however, there is an informal role for BI and its contribu-
tion to reimbursement decisions often remains unclear. As a 
result of that, the role of BI in decision-making remains an 
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important topic for debate [1, 5, 6]. In particular, the grow-
ing attention for healthcare and pharmaceutical expenditures 
in combination with price negotiation mechanisms increas-
ingly raises questions about the role of cost-effectiveness 
(CE).
Whilst the role of BI is often unclear in reimbursement 
decision-making, there are ample examples where BI did 
play a significant role in either the reimbursement decisions 
or where high BI estimates resulted in restricted reimburse-
ment for a specific patient population [6–11]. Recently, the 
introduction of new, very effective but high priced Direct-
acting antivirals (DAA) in hepatitis C sparked worldwide 
affordability concerns and access restrictions [7, 8]. Also in 
oncology, patients have limited access to many high priced 
products due to concerns regarding affordability as a result 
of high BI [9–11].
Especially in the hepatitis C case, the cost-effectiveness 
of the innovations were generally regarded as positive and 
medical need was high [12–16]. The future will bring new 
products with potentially high short-term BI, which could 
spark further BI-guided restrictions and will call for further 
deliberation of the role of affordability in the political and 
societal debate and as such of relevant meaning in health-
care decision-making [17, 18]. Therefore, clarity on the role 
and hierarchy of CE vs BI will not only be of interest but 
seems to become very important in informing reimburse-
ment decisions.
Unfortunately, the (methodological) quality and accuracy 
of BI analysis does not seem to match the proven scientific 
rigor of CEAs [6, 19, 20]. A review by Van de Vooren et al. 
[21] reports that (methodological) quality of many published 
BI analyses is poor. Furthermore, Broder et al. and Cha et al. 
illustrate that the accuracy of BI predictions is regarded as 
low [22, 23]. These observations, in light of the increased 
debate on drug prices, growing interest in price negotiation, 
BI of pharmaceuticals as part of healthcare budgets (e.g. 
Hospital) and, therefore, burden to societies, warrant ques-
tions about whether BI is being used properly and what the 
extent of influence is on patient access.
In this paper, the accuracy and role of BI in reimburse-
ment decisions is investigated by assessing the life cycle of 
hepatitis C DAAs in the Netherlands. This case was selected 
as there were concerns for an extremely high BI (up to €1.78 
billion). The final reimbursement decision of Sofosbuvir 
(Sovaldi), the first DAA, resulted in restricting treatment to 
the most critically ill whilst this seems rather irrational from 
a cost-effectiveness perspective and was likely triggered by 
other elements such as price, BI considerations and afford-
ability discussions [12, 13, 24–28].
The aim of this hepatitis C case study is twofold: First, 
we aim to quantify the accuracy of the BI predictions used 
for informing the Dutch reimbursement decisions. Second, 
we attempt to characterize the influence of market-dynamics 
on actual BI and the way these are implemented in the BI 
predictions. This includes, for example, timing of regula-
tory decisions, influence of introductions of new hepatitis 
C products and the influence of a restricted reimbursement 
decision that limits the product’s indication.
Methods
Product inclusion
We included hepatitis C DAAs that were mainly designated 
a standalone option for treatment of hepatitis C according to 
the EASL guidelines, thereby not considering co-treatment 
with ribavirin and/or pegylated interferon [29–32]. We sub-
sequently excluded products that were not introduced or 
not used in the Netherlands in the period from 1 Jan 2014 
to 1 March 2018. Lack of use or introduction was based 
on a publicly available national drug information system 
(GIP), which has national coverage and is maintained by the 
National Health Care Institute (ZIN) [33].
Daclatasvir (Daklinza) and simeprevir (Olysio) were 
excluded as these products are mainly used in combina-
tion with sofosbuvir (Sovaldi) but not as monotherapy. The 
sofosbuvir/velpatasvir/voxilaprevir (Vosevi) combination 
was not introduced and is thus excluded. Sovaldi, sofosbu-
vir/ledipasvir (Harvoni), ombitasvir/paritaprevir/ritonavir 
(Viekirax) + dasabuvir (Exviera), sofosbuvir/velpatasvir 
(Epclusa), elbasvir/grazoprevir (Zepatier) and glecaprevir/
pibrentasvir (Maviret) were included.
BI data and BI estimation accuracy
The actual Dutch BI data was provided by FarmInform 
[34]. The population-level data of FarmInform comprises 
of monthly volume of all prescription drugs in the in- and 
outpatient setting multiplied by the respective monthly list 
price in the Netherlands [35]. Validity of the data is ensured 
as the data is crosschecked with patient-level data that is 
representative of the Netherlands (PHARMO) [36, 37]. As 
DAAs target specific hepatitis C viral proteins, off-label use 
of DAAs is highly unlikely and we, therefore, assume that 
all DAA BI is used for treatment of hepatitis C.
The BI estimates used to inform the reimbursement 
decisions of hepatitis C therapy in the Netherlands were 
collected from the published and publicly available ZIN 
reimbursement dossiers [12, 13, 24–27, 38]. These dossiers 
typically project the BI for the 3 years after publication of 
the dossier. The ZIN BI estimation format and methodology 
are based on the most recent ISPOR guidelines for conduct-
ing BI analysis [39, 40]. BI is based on market potential: it 
accounts for expected patient populations and one or more 
treatment regimens and associated costs [39, 40]. Correction 
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should be performed for 1st in class vs subsequent introduc-
tions by making assumptions regarding the market penetra-
tion [39]. It is also recommended to include the effects of 
restrictions in indication due to the eventual reimbursement 
decision [39].
The treatment regimens or subpopulations that are men-
tioned in the reimbursement dossiers are based on (com-
binations of) METAVIR score, genotype, IFN or ribavirin 
co-medication and prior treatment experience. From the 
dossiers, estimated BI, population size and average treat-
ment costs were recorded, as well as the subpopulations and 
the aforementioned characteristics these estimations were 
based on. The BI prediction accuracy was then assessed by 
comparing the ZIN BI estimates with the real world actual 
BI data for all included products.
Treatment indication and resulting access
As there was a potential for significant budget impact, the 
Sovaldi reimbursement decision stated treatment was to be 
restricted to more severely ill patients [28]. To investigate 
the effect and extent of this reimbursement restriction and 
the development of access when DAAs without restric-
tions were introduced, we aimed to quantify the amount of 
DAA access by translating actual BI to a number of patients 
treated.
Number of patients treated was calculated as follows:
As BI is known from the actual BI data, average treatment 
cost per patient had to be established. Each product has a 
standard treatment duration (12 weeks for most products, 
8 weeks for Maviret) that can be multiplied by the known 
list price to obtain the cost of treating one patient. Some sub-
populations, however, require a longer treatment duration:
• Genotype: The hepatis C virus is classified in six geno-
types. They differ in susceptibility to (DAA) treatment 
as GT 3 typically requires longer treatment [29, 31, 32, 
41, 42].
• Severity of disease: More severe disease evidently war-
rants not only (more) immediate treatment but also 
longer treatment [29, 31, 32].
• Prior treatment: Treatment experienced patients in some 
cases require longer treatment [31, 32].
Chronic hepatitis C disease severity is frequently catego-
rized using the well-validated METAVIR scoring system 
[43, 44]. This five point scale distinguishes between various 
stages of liver fibrosis where F0 = no fibrosis, F1 = portal 
fibrosis without septa, F2 = portal fibrosis with rare septa, 
F3 = numerous septa without cirrhosis, F4 = cirrhosis [43, 
Number of patients treated =
Budget impact
Average treatment cost per patient
.
44]. For clarity, we do not consider extrahepatic complica-
tions of hepatitis C, and thus solely reflect disease severity 
by means of METAVIR score.
EASL guidelines on treatment of particular METAVIR 
scores changed particularly:
• EASL 2014 and 2015: All patients with chronic liver 
disease related to HCV should be considered for therapy. 
Treatment should be prioritized in patients with META-
VIR score F3 and F4. Treatment is justified in patients 
with METAVIR score F2. The timing and nature of ther-
apy for patients with METAVIR score F0 + F1 debatable, 
and informed deferral can be considered [29, 30].
• EASL 2016: All patients with chronic liver disease 
related to HCV must be considered for therapy. Treat-
ment must be considered without delay in patients with 
METAVIR score F2–F4 [31].
• EASL 2018: All patients with HCV infection should be 
treated. Treatment must be considered without delay in 
patients with METAVIR score F2–F4 [32].
The influence of these factors on treatment duration 
changed over time as the leading European Association 
for the study of the Liver (EASL) hepatitis C guidelines 
changed and new DAAs were introduced [29–32]. Supple-
mental Table 1 summarizes the major exceptions regarding 
treatment duration for various subpopulations.
Mean treatment costs per product
As, in for example the case of Harvoni, METAVIR stage 
F4 indicates a longer treatment duration, a larger propor-
tion of patients with stage F4 would increase average treat-
ment costs. This is of particular interest as the Harvoni and 
Viekirax + Exviera, dossiers specifically address 3 national 
BI scenarios based on only treating patients with F4 + F3 
(scenario A), F4–F2 (scenario B) and F4–F0 (scenario C) 
[12, 26]. Average treatment costs thus differ per scenario. To 
be able to adjust average treatment costs to different scenar-
ios, the ZIN BI calculations had to be recreated so that the 
influence of different populations could be assessed. Average 
treatment costs per patient were solely recreated using the 
assumptions and data from the respective reimbursement 
dossiers.
In the reimbursement dossiers, the following assumptions 
for the Dutch setting were made: The genotype distribution 
is 49% GT1, 10% GT2, 29% GT3 and 11% GT4, GT5 and 
GT6 are very rare in the Netherlands [13, 41, 45]. Sovaldi 
treatment regimens for GT2 and GT3 are IFN free whilst for 
GT1, GT4–6 30% of patient will be treated with an IFN free 
regimen [13]. The METAVIR distribution is assumed to be 
24.9% F0, 26% F1, 16.1% F2, 16.8% F3, 16.2% F4 [12]. ZIN 
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states that the total number of chronic HCV patients, thus 
from F0–F4 and GT1–4, in The Netherlands is between 2000 
and 3000 (29). With a population of 16.9 million at the time 
of publication, this implies a prevalence of 0.012–0.018% 
[46].
The reimbursement dossiers of Sovaldi, Harvoni and 
Viekirax + Exviera provided detailed insights into the types 
of patients receiving specific treatment durations, costs 
and various calculations [12, 13, 26]. For these products 
we were, therefore, able to calculate scenario/population 
dependent average treatment costs.
For Epclusa, Zepatier and Maviret, only a short reim-
bursement report with rudimentary budget impact predic-
tion was published [24, 25, 27]. These BI estimations lacked 
detailed assessments of treatment duration per subpopula-
tion. In our analysis, we, therefore, assumed the following:
• Maviret: We assume that all patients are treatment naïve 
as we have no valid data regarding the distribution of 
treatment experienced vs treatment naïve patients. That 
implies that, according to the ZIN reimbursement dos-
sier, all F0–F3 patients receive 8 weeks of treatment and 
F4 patients are treated for 12 weeks [25].
• Zepatier: The only exceptions to the standard 12 weeks 
treatment are in cases where HCV RNA > 800,000 IU/
ML [27, 31]. As we have no clear data on the number of 
patients in the Dutch setting, we disregard this exception 
and assume all patients are treated for 12 weeks.
• Epclusa: There are no exceptions to the standard 
12  weeks treatment duration so we assume that all 
patients are treated for 12 weeks [24, 31].
For our base–case analysis, we take the average of the 
estimated patient population size at 2500 (range 2000–3000). 
We, furthermore, use treatment costs of the F4–F2 (B) sce-
nario. Changes in list-price over time were corrected using 
the G-standard, a database that contains the monthly list-
prices of all Dutch prescription drugs so that the correct 
amount of patients are calculated [35]. We did not incorpo-
rate EASL guideline changes in our analyses.
Sensitivity analyses
By means of sensitivity analysis, we investigate the scenar-
ios proposed in the reimbursement dossier that we did not 
use as base–case scenario. We thus investigate the influence 
of a different population size and treatment cost. For popula-
tion size, we take the minimum (2000) and maximum (3000) 
values of the range that was estimated in the reimbursement 
dossiers. Furthermore, we investigate the influence of aver-
age treatment cost per patient by using the F4 + F3 (A) and 
F4–F0 (C) scenarios. Additionally, we perform an analysis 
with the absolute minimum treatment cost where we assume 
that no patients get extended treatment regimens for any of 
the included products. Finally, we assess the influence of 
GT3 prevalence on average treatment costs as this genotype 
generally warrants a longer, and thus a more costly treat-
ment. We, therefore, increase GT3 prevalence from 30 to 
50%, which is higher than the reported GT3 prevalence in 
any European country, decrease GT1 prevalence from 50 to 
30% and recalculate the average treatment costs [42].
Results
Accuracy of BI estimates
We compared the estimated BI from reimbursement reports 
with the actual BI. The estimated BI timeline starts at the 
date at which national reimbursement was granted except 
when an explicit period was mentioned. As mentioned 
before, the Sovaldi reimbursement decision restricted treat-
ment to F4 + F3. The eventual reimbursement decisions for 
Harvoni and Viekirax + Exviera were without restrictions, 
meaning that scenario C (F4–F0) had been adopted. Maviret, 
Epclusa and Zepatier were also reimbursed without restric-
tion but for these products, no a priori scenarios were made. 
Figure 1 displays the actual BI and estimated BI for the only 
four products with a reported estimated BI. BI overestima-
tion is apparent for all products with respect to their eventual 
reimbursement decision. For Harvoni and Viekirax + Exvi-
era, the lower F4 + F3 scenario is closer to the actual BI than 
the adopted scenario.
Figure 2 combines the monthly BI of the individual prod-
ucts and shows the total BI of these four products. BI initially 
peaks with the introduction of Sovaldi to a monthly BI of 
about €8 million in the first quarter of 2015. Then, with the 
introduction of Viekirax + Exviera and Harvoni, a monthly 
BI of €14 million is reached and sustained for 4 months. 
In Fig. 3 we display the relative market share of the four 
products with an estimated BI, including the cumulative BI. 
The cumulative BI shows that in about 4 years, €250 million 
was spent on the four DAAs. The assumed market share of 
Harvoni (35%) and Viekirax + Exviera (35%) was, in reality, 
between 40–60% and < 10%, respectively.
The total actual BI, estimated BI and total absolute 
deviation per individual product and for the total cohort are 
denoted in Table 1. Table 2 displays the standard treatment 
duration per product, the eventual average treatment costs 
per product and, if applicable, per scenario. Even with the 
most modest treatment scenario (F4 + F3), treatment costs 
were overestimated at €153 million. When extending to the 
adopted and most inclusive treatment regimen (F4–F0), 
total overestimation increases to €275 million. As the time 
between introduction of Sovaldi (1 Jan 2014) until the last 
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Fig. 1  Estimated BI vs Actual 
BI, values are in € millions and 
per month
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data-point (1 Mar 2018) is slightly over 4 years, the annual 
overestimation of hepatitis C treatment costs are around 
€38–€69 million.
Analysis of market dynamics
The actual number of patients treated per month is visual-
ized in Fig. 4. The theoretical number of patients in differ-
ent METAVIR categories indicate the extent of treatment 
availability to various degrees of disease severity where we 
assume that treatment is prioritized according to METAVIR 
score. On the x-axis, date of granting European Medicines 
Agency (EMA) Marketing Authorization (MA) and the date 
of the formal initiation of national reimbursement are dis-
played. Note that a formal reimbursement status decision 
comes from the Minister of Health following an advice from 
ZIN.
It is evident that Sovaldi and Harvoni, at least until 2017, 
were most frequently used. Interestingly, for almost entire 
2014, access was very limited due to absent reimbursement 
whilst EMA MA was granted in January. It seems that at 
least patients with METAVIR F4 and F3 were treated from 
2015 onwards. For 2015 and 2016, treatment appears to 
have been extended to F2. The increase to F0 at the start of 
(unrestricted) reimbursement of Harvoni could be explained 
by the fact that treatment then became available for F2–F0 
patients.
Apart from the initial peak of Harvoni and Sovaldi, 
broadening of the treatment population over time, as is rec-
ommended by the EASL guidelines and as is permitted by 
the reimbursement decisions of all products but Sovaldi, 
seems to be absent. This is apparent as from 2017 onwards, 
treated patient numbers remain stable at a level only encom-
passing the F3 and F4 patients. The rise in treated patients 
around the reimbursement date clearly confirm that in The 
Fig. 2  Total monthly BI. Total BI and Sovaldi BI overlap until 1 Sep 
2015 as Sovaldi is then the only product
Fig. 3  Share of BI per product on the left vertical axis. Cumulative 
BI (in millions) of all four products is shown in the right vertical axis
Table 1  Overview of Actual BI, 
Estimated BI and the difference 
between actual- and estimated 
BI. A negative difference 
implies an overestimation of BI
a The eventual reimbursement decision
Product (METAVIR score) Actual BI (€) Estimated BI (€) Difference (€)
Sovaldi 128,692,991 281,166,336 − 165,151,871
Harvoni (F4 + F3) 91,461,345 54,495,833 36,796,849
Harvoni (F4–F2) 91,461,345 76,004,167 15,457,178
Harvoni (F4–F0)a 91,461,345 143,550,000 − 52,257,318
Viekirax + Exviera (F4 + F3) 10,557,104 24,166,667 − 13,609,563
Viekirax + Exviera (F4–F2) 10,557,104 32,020,833 − 21,463,730
Viekirax + Exviera (F4–F0)a 10,557,104 57,033,333 − 46,476,230
Epclusa 17,632,950 29,000,000 − 11,413,049
Total (F4–F3) 248,344,389 388,828,836 − 153,377,635
Total (F4–F2) 248,344,389 418,191,336 − 182,571,472
Total (F4–F0) 248,344,389 510,749,669 − 275,298,468
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Netherlands, access is governed by national coverage deci-
sions and not by EMA MA.
We compared our patient estimates with the publicly 
available national GIP drug information system to ensure 
validity of our approach [33]. In supplemental Table 2 we 
extracted the annual number of users per product and they 
are reasonably comparable with our monthly estimates as 
displayed in Fig. 4.
Sensitivity analyses
The different treatment costs used are displayed in Table 2. 
The sensitivity analyses show that the estimated size of 
the patient population has some influence with larger total 
populations yielding less access for more favorable META-
VIR scores as a smaller fraction of the population appears 
to be treated. Supplemental Fig. 6 (treatment scenario C 
and base–case population size) shows the data based on the 
eventual reimbursement decisions for Harvoni and Viekirax 
& Exviera. Treatment scenarios A and C vary little com-
pared to scenario B that was used as base–case. The mini-
mum treatment cost scenario disregards any possibility for 
extended treatment durations for various subpopulations. 
This scenario thus results in a higher number of patients 
treated as treatment costs per patient were lower.
We explored the influence of GT3 prevalence on average 
treatment costs. For Harvoni and the various scenarios, aver-
age treatment costs increased with 7.5–13% whereas average 
Sovaldi treatment costs increased with 12–15%. Viekirax 
and Exviera are not recommended for GT3 and the reported 
treatment costs of Epclusa, Zepatier and Maviret are not 
influenced by genotype. Given that the GT3 prevalence 
increase from 30 to 50% is a 67% increase, we can conclude 
that average treatment costs are relatively insensitive to GT3 
prevalence.
Discussion
In a Dutch setting, we showed that BI estimates reported 
in ZIN reimbursement dossiers largely overestimated the 
actual BI for hepatitis C DAAs. Although the most severely 
ill patients did get access to the innovative hepatitis C 
Table 2  Average treatment cost 
per patient per reimbursement 
scenario
a The eventual reimbursement decision
Product Treatment 













Sovaldi 73,153 73,153 73,153 48,000 12
Harvoni 85,936 80,383 74,589a 51,750 12
Viekirax + Exviera 57,959 51,444 45,172a 39,400 12
Epclusa 45,999 45,999 45,999 45,999 12
Zepatier 41,397 41,397 41,397 41,397 12
Maviret 30,666 30,666 30,666 30,666 8
Fig. 4  Treated patients over 
time, with monthly data. Dotted 
lines indicate the assumed num-
ber of patients with a specific 
METAVIR score. Circles indi-
cate the date of EMA Market-
ing Authorization, diamonds 
indicate the date of positive 
reimbursement decision
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therapies, access was initially not granted to the extent of the 
recommendations in the then prevailing EASL guidelines.
In the EU, the crude hepatitis C incidence is estimated 
to be 7.4 per 100,000 persons but with a very large spread 
(0.1–73.3) between countries, at least partly driven by vary-
ing quality of surveillance systems and data completeness 
[47–49]. ZIN dossiers as well as studies by Iyengar et al., 
Cornberg et al. and Saraswat et al. report larger potential eli-
gible populations (22,000–28,000, 0.14–0.17%) than those 
that ZIN actually used for the BI calculations (2000–3000, 
0.012–0.018%) [12, 48–50]. The former population, all those 
with chronic hepatitis C, should be treated according to the 
most recent EASL guideline. Interestingly, the estimates of 
28,000 stated in the reimbursement dossiers are denoted as a 
scenario where the ‘indication is broadened’ to all hepatitis 
C patients. No further notion is given as to whether the pre-
sumable non-symptomatic patients are actually F0 patients. 
We can safely conclude that (1) current patient volumes have 
not been near this level and (2) the estimates of 2000–3000 
are likely to be a conservative estimate.
In 2015, when Sovaldi was reimbursed, the BI and esti-
mates of number of patients appear to be rather accurate as 
we see that, according to the reimbursed indication, treated 
patients are within the F4–F3/F2 range. Then, with the unre-
stricted reimbursement of Harvoni and Viekirax + Exviera, 
treated patients plateau to the predicted F4–F0 population 
for approximately 4 months. These observations would 
suggest that the ZIN estimate of 2000–3000 patients per 
year is quite accurate. From June 2016 onwards, however, 
patient numbers decline to an F4 + F3 level that is below 
the expected F4–F0 range. If we, for now, assume that the 
estimate of number of patients was indeed reasonably accu-
rate, other factors must have been responsible for the large 
deviations between estimated and actual BI.
A first reason for this deviation could be the inadequate 
implementation of timing of regulatory decisions. The 
Sovaldi reimbursement dossier was published on 20 May 
2014 based on which ZIN formally advised the minister of 
health on 23 May 2014. The final reimbursement status was 
granted per 1 Nov 2014. The delay between advice and reim-
bursement could have been unforeseen. The manufacturer 
and/or ZIN could, however, have assumed that reimburse-
ment of Sovaldi during entire 2014 (MA was 16 Jan 2014) 
was highly unlikely. Still, the BI estimate assumed access 
during the entire year. This alone contributed to a €46 mil-
lion overestimation which could have been prevented. Of 
course, the relevancy of this overestimation can be ques-
tioned as it is common-practice to start the period of esti-
mation from the initiation of reimbursement. Applying this 
logic would shift the Sovaldi ‘Estimated BI’ line in Fig. 1 to 
the right and would cause a nearly equal overestimation from 
01 Jan 2017 onwards due to declined market share.
In line with the overestimation due to a declined market 
share, inadequate correction for the introduction of new 
products could be a second reason. The Sovaldi BI esti-
mations did not at all account for the introduction of new 
products in the same class whilst this was nearly inevita-
ble as various manufacturers were in advanced stages of 
clinical development or regulatory approval [30, 51, 52]. 
The ISPOR BI guideline, to which ZIN refers in their own 
guidance on BI, states that an attempt should be made 
to forecast introduction of new interventions for the cho-
sen time horizon [39]. Harvoni and Viekirax + Exviera 
were introduced nearly simultaneously and both were 
estimated to reach a market share of 35%. As our results 
show, the latter product only reached a small fraction of 
the estimated 35% whilst the former outperformed the 
expectations.
Of course, the patient estimates or the distribution over 
METAVIR scores could have been inaccurate. In addition, as 
DAA BI was in general overestimated and patient estimates 
are on the low side of estimations, we should consider the 
possibility that other forms of access restrictions were pre-
sent. Stringent reimbursement criteria or volume caps issued 
to hospitals by payers might have been a factor in this regard 
as payers in The Netherlands have gained influence [53].
Transitioning towards the role BI played in governing 
access for this specific case study, we like to reiterate that 
actual BI stayed well below the BI estimations ZIN deemed 
realistic. Consequently, the actual BI was also considerably 
lower than alternative scenarios postulated by ZIN where a 
‘broader DAA indication’ would be adopted. This, accord-
ing to the reimbursement dossiers, could theoretically lead 
to a BI of €1.78 billion [12]. Such a wide call for treating 
all viraemic hepatitis C patients, culminating in the EASL’s 
2018 guideline recommendation, has not been apparent in 
our data. Our data did, however, show that access is strictly 
governed by a positive reimbursement decision as a prod-
ucts’ BI is very low before it is reimbursed.
The reimbursement decision was, on average, taken 
258 days after MA whilst the reimbursement dossier was 
published after on average 117 days. Price negotiations were 
conducted for all products for which the HTA report was 
used as guidance. There is, however, no report on the role 
that BI played in this process and whether BI estimations, 
which are known and proven to be uncertain, are necessary 
for either the reimbursement decision or the price negotia-
tion. Additionally, one can extend this way of thinking with 
a debate on whether the 258 days of access restriction is 
worthwhile. This especially in light of the fact that DAAs 
are generally considered cost-effective [12–16].
The implications of over- and underestimations differ 
for various stakeholders. Patients and manufacturers of the 
specified products, would probably incur no real loss due to 
an initial underestimation. It could potentially even facilitate 
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the reimbursement process whereas the contrary could be 
true for an initial overestimation. For payers, however, an 
underestimation could be more troublesome than an over-
estimation as the former could cause direct and measurable 
budgetary deficits. We have no evidence to support or quan-
tify these statements, but it is known that payers and manu-
facturers have confidential price negotiations where their BI 
estimates together with other parameters serve some purpose 
for bargaining [54].
If there is a more aligned and agreed estimate of patient 
numbers, as the basis of a BIA, we believe that more accu-
rate BI estimates are achievable. As is stated in the most 
recent BIA guideline, it is important to include treatment 
dynamics including new introductions and displacement 
effects as well as pricing dynamics to provide more accu-
rate and meaningful BI estimates. This would allow for a 
more prominent role and value of BI in the decision-making 
process for reimbursement of different types of treatments 
(e.g. chronic and one-off).
Our study has various strengths. First, we used real world 
data to assess access using validated and monthly updated 
data. Our data covers in- and outpatient dispensing data, is 
irrespective of the healthcare provider or insurance company 
and, therefore, captures the entire Dutch DAA access data.
Second, we made an accurate representation of average 
treatment cost per patient using the distribution of several 
subpopulations. As our sensitivity analysis shows, not 
including patients with longer than typical treatment dura-
tions have a profound influence on outcomes.
Our study also has some limitations. First, several 
assumptions underlie population size estimates and the dis-
tribution of subgroup characteristics. We, therefore, cross-
checked our estimates with the GIP-database which reports 
comparable figures [33]. We, furthermore, aimed to illustrate 
the influence of population size and treatment costs on out-
comes by means of sensitivity analysis.
Second, our Dutch scenario induces limitations regard-
ing generalizability. Of course, the Dutch healthcare and 
reimbursement system is not directly comparable to others 
but the, albeit imperfect, method of BI estimation is rather 
similar [21–23, 39].
Third, confidential discounts or rebates are not included 
in this analysis. In the Netherlands, the general outcome 
of price negotiations is published but the actual discount 
remains confidential. A study by Morgan et al. indicated 
that, in ten high-income countries (including The Nether-
lands), discounts are common and confidential discounts 
are most frequently in the 20–29% range but can also be 
substantially higher (> 60%) [55]. We thus know that the 
actual BI, as costs to society, are lower than presented here. 
Yet, we based our analyses on BI estimations that disregard 
potential discounts and rebates. Lack of inclusion of pricing 
agreements is, therefore, not a concern.
Conclusion
The BI estimates published by ZIN provide a substantial 
overestimation of the actual BI with a deviation of between 
€153–€275 million. The number of treated patients 
remains low, especially in light of the much higher inci-
dence of viraemic hepatitis C and the most recent EASL 
guideline recommending treatment for this entire popu-
lation. Underlying patient number that were used for BI 
estimates seem to be at least somewhat overestimated but 
are probably not the sole cause of BI overestimations. Dif-
ferences could potentially be caused by inadequate correc-
tion for (timing of) regulatory decisions, reimbursement 
for a limited indication and insufficient incorporation of 
the introduction of new products. These market dynam-
ics are, to varying extent, unanticipated but could and 
should at least partly be corrected for. When BIA is per-
formed according to existing guidelines, the resulting 
more accurate BI estimates can lead to better informed 
reimbursement decisions. Currently, it is unclear how the 
BI estimates informed the reimbursement decision and if 
different decisions would have been if more accurate BI 
estimates been had available. In light of increasing debate 
on prices, the (uncertain) role of the reimbursement dos-
sier in confidential price negotiations and an increasing 
pressure on healthcare budgets in general, it is important 
to further develop an approach to use BI as a more inte-
grated part of healthcare decision-making processes.
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